Locoregional recurrence risk after lipofilling in breast cancer patients

J. Y. Petit, E. Botteri, V. Lohsiriwat, M. Rietjens, F. De lorenzi, C. Garusi, F. Rossetto, S. Martella, A. Manconi, F. Bertolini, G. Curigliano, P. Veronesi, B. Santillo, N. Rotmensz

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Background: Lipofilling has been indicated for postmastectomy and postlumpectomy breast reconstruction. The clinical literatures underline its technical efficacy but experimental studies raise important questions about the potential detrimental effect of adipocytes on the stimulation of cancer growth and reappearance. Design: We collected 321 consecutive patients operated for a primary breast cancer between 1997 and 2008 who subsequently underwent lipofilling for reconstructive purpose. For each patient, we selected two matched patients with similar characteristics who did not undergo a lipofilling. Results: Eighty-nine percent of the tumors were invasive. Median follow-up was 56 months from the primary surgery and 26 months from the lipofilling. Eight and 19 patients had a local event in the lipofilling and control group, respectively, leading to comparable cumulative incidence curves [P = 0.792; Hazard Ratio Lipo vs No lipo = 1.11 (95% confidence interval 0.47-2.64)]. These results were confirmed when patients undergoing quadrantectomy and mastectomy were analyzed separately and when the analysis was limited to invasive tumors. Based on 37 cases, the lipofilling group resulted at higher risk of local events when the analysis was limited to intraepithelial neoplasia. Conclusions: Lipofilling seems to be a safe procedure in breast cancer patients. Longer follow-up and further experiences from oncological series are urgently required to confirm these findings.

Original languageEnglish
Pages (from-to)582-588
Number of pages7
JournalAnnals of Oncology
Volume23
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Breast Neoplasms
Recurrence
Neoplasms
Mammaplasty
Mastectomy
Adipocytes
Confidence Intervals
Control Groups
Incidence
Growth

Keywords

  • Breast cancer
  • Breast reconstruction
  • Fat grafting
  • Lipofilling
  • Lipotransfer
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Locoregional recurrence risk after lipofilling in breast cancer patients. / Petit, J. Y.; Botteri, E.; Lohsiriwat, V.; Rietjens, M.; De lorenzi, F.; Garusi, C.; Rossetto, F.; Martella, S.; Manconi, A.; Bertolini, F.; Curigliano, G.; Veronesi, P.; Santillo, B.; Rotmensz, N.

In: Annals of Oncology, Vol. 23, No. 3, 03.2012, p. 582-588.

Research output: Contribution to journalArticle

@article{c91c1bcb4ebd441e98b39fbee691a4c9,
title = "Locoregional recurrence risk after lipofilling in breast cancer patients",
abstract = "Background: Lipofilling has been indicated for postmastectomy and postlumpectomy breast reconstruction. The clinical literatures underline its technical efficacy but experimental studies raise important questions about the potential detrimental effect of adipocytes on the stimulation of cancer growth and reappearance. Design: We collected 321 consecutive patients operated for a primary breast cancer between 1997 and 2008 who subsequently underwent lipofilling for reconstructive purpose. For each patient, we selected two matched patients with similar characteristics who did not undergo a lipofilling. Results: Eighty-nine percent of the tumors were invasive. Median follow-up was 56 months from the primary surgery and 26 months from the lipofilling. Eight and 19 patients had a local event in the lipofilling and control group, respectively, leading to comparable cumulative incidence curves [P = 0.792; Hazard Ratio Lipo vs No lipo = 1.11 (95{\%} confidence interval 0.47-2.64)]. These results were confirmed when patients undergoing quadrantectomy and mastectomy were analyzed separately and when the analysis was limited to invasive tumors. Based on 37 cases, the lipofilling group resulted at higher risk of local events when the analysis was limited to intraepithelial neoplasia. Conclusions: Lipofilling seems to be a safe procedure in breast cancer patients. Longer follow-up and further experiences from oncological series are urgently required to confirm these findings.",
keywords = "Breast cancer, Breast reconstruction, Fat grafting, Lipofilling, Lipotransfer, Recurrence",
author = "Petit, {J. Y.} and E. Botteri and V. Lohsiriwat and M. Rietjens and {De lorenzi}, F. and C. Garusi and F. Rossetto and S. Martella and A. Manconi and F. Bertolini and G. Curigliano and P. Veronesi and B. Santillo and N. Rotmensz",
year = "2012",
month = "3",
doi = "10.1093/annonc/mdr158",
language = "English",
volume = "23",
pages = "582--588",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Locoregional recurrence risk after lipofilling in breast cancer patients

AU - Petit, J. Y.

AU - Botteri, E.

AU - Lohsiriwat, V.

AU - Rietjens, M.

AU - De lorenzi, F.

AU - Garusi, C.

AU - Rossetto, F.

AU - Martella, S.

AU - Manconi, A.

AU - Bertolini, F.

AU - Curigliano, G.

AU - Veronesi, P.

AU - Santillo, B.

AU - Rotmensz, N.

PY - 2012/3

Y1 - 2012/3

N2 - Background: Lipofilling has been indicated for postmastectomy and postlumpectomy breast reconstruction. The clinical literatures underline its technical efficacy but experimental studies raise important questions about the potential detrimental effect of adipocytes on the stimulation of cancer growth and reappearance. Design: We collected 321 consecutive patients operated for a primary breast cancer between 1997 and 2008 who subsequently underwent lipofilling for reconstructive purpose. For each patient, we selected two matched patients with similar characteristics who did not undergo a lipofilling. Results: Eighty-nine percent of the tumors were invasive. Median follow-up was 56 months from the primary surgery and 26 months from the lipofilling. Eight and 19 patients had a local event in the lipofilling and control group, respectively, leading to comparable cumulative incidence curves [P = 0.792; Hazard Ratio Lipo vs No lipo = 1.11 (95% confidence interval 0.47-2.64)]. These results were confirmed when patients undergoing quadrantectomy and mastectomy were analyzed separately and when the analysis was limited to invasive tumors. Based on 37 cases, the lipofilling group resulted at higher risk of local events when the analysis was limited to intraepithelial neoplasia. Conclusions: Lipofilling seems to be a safe procedure in breast cancer patients. Longer follow-up and further experiences from oncological series are urgently required to confirm these findings.

AB - Background: Lipofilling has been indicated for postmastectomy and postlumpectomy breast reconstruction. The clinical literatures underline its technical efficacy but experimental studies raise important questions about the potential detrimental effect of adipocytes on the stimulation of cancer growth and reappearance. Design: We collected 321 consecutive patients operated for a primary breast cancer between 1997 and 2008 who subsequently underwent lipofilling for reconstructive purpose. For each patient, we selected two matched patients with similar characteristics who did not undergo a lipofilling. Results: Eighty-nine percent of the tumors were invasive. Median follow-up was 56 months from the primary surgery and 26 months from the lipofilling. Eight and 19 patients had a local event in the lipofilling and control group, respectively, leading to comparable cumulative incidence curves [P = 0.792; Hazard Ratio Lipo vs No lipo = 1.11 (95% confidence interval 0.47-2.64)]. These results were confirmed when patients undergoing quadrantectomy and mastectomy were analyzed separately and when the analysis was limited to invasive tumors. Based on 37 cases, the lipofilling group resulted at higher risk of local events when the analysis was limited to intraepithelial neoplasia. Conclusions: Lipofilling seems to be a safe procedure in breast cancer patients. Longer follow-up and further experiences from oncological series are urgently required to confirm these findings.

KW - Breast cancer

KW - Breast reconstruction

KW - Fat grafting

KW - Lipofilling

KW - Lipotransfer

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84857580620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857580620&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr158

DO - 10.1093/annonc/mdr158

M3 - Article

C2 - 21610155

AN - SCOPUS:84857580620

VL - 23

SP - 582

EP - 588

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -